Navigation Links
Pipeline Insight: Gastrointestinal Cancer Overview - Metastatic Gastrointestinal Cancers Represent a Significant Commercial Opportunity Due to a Lack of Approved Drugs
Date:11/4/2010

inclusion as part of the Phase III trial endpoints 48

Clinical efficacy of brivanib could be enhanced if Phase III development was alongside chemotherapy... 48

...as could eventual uptake in the second-line colorectal cancer setting 49

Bristol-Myers Squibb offers ideal credentials to ensure brivanib's potential in colorectal cancer is maximized 49

Satisfaction of unmet needs 49

Forecasts to 2019 50

Recentin (cediranib; AstraZeneca) 51

Drug overview 51

Drug profile 51

Key historical events 52

Clinical trial data 53

Top-line results from the Phase III HORIZON III study failed to show any benefit of Recentin over Avastin in combination with first-line chemotherapy 54

Phase II results show Avastin to confer greater progression-free survival alongside standard second-line chemotherapy than Recentin 54

SWOT analysis 55

Datamonitor drug assessment scorecard for Recentin 55

Clinical and commercial attractiveness 56

Phase III HORIZON III results mean Recentin will find it difficult to compete in the first-line setting... 56

...while the ongoing Phase III HORIZON II study is high-risk 57

Avastin's mode of action and formulation may be more effective than Recentin's 57

Targeting the Japanese market? 57

AstraZeneca's strength in the oncology market will be key in Recentin's success 58

Satisfaction of unmet needs 58

Forecasts to 2019 59

4. Esophageal Cancer 60

Key findings 60

Disease overview 60

Definition 60

Esophageal cancer is a major source of cancer-related death 60

Patient segmentation 61

Esophageal cancer has been pathologically staged since 2002 61

Epidemiology 62

Seven major markets 62

Rest of the world 64

Current treatment options 64

Current comparator therapy 66

Xeloda (capecitabine; Roche) 66

Unmet need in esophageal ca
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine technology :

1. Karyopharm Therapeutics Inc. Closes $20 Million Series A Financing to Advance Pipeline of Novel Nuclear Transport Modulators for Cancer, Inflammation and Other Disorders
2. Tengion Reviews Pipeline Progress at First Analyst and Investor Meeting; Strategic & Clinical Updates Provided for Regenerative Medicine Programs
3. Lexicon to Provide Clinical Pipeline Update and Report Third Quarter 2010 Financial Results
4. Reportlinker Adds Commercializing Cancer Vaccines: A Decision Support Tool for Optimizing the Pipeline
5. Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Now Available at ReportsandReports
6. Updated Pfizer Pipeline Focuses on Value, Unmet Medical Need
7. Reportlinker Adds Electrophysiology Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016
8. Reportlinker Adds Prosthetic Heart Valves - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016
9. Abbott to Present Data on Market-Leading XIENCE V® and Promising Vascular Pipeline at TCT 2010
10. Reportlinker Adds Interventional Cardiology Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016
11. Reportlinker Adds Global Renal Dialysis Equipment Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Sept. 2, 2014 /PRNewswire-iReach/ -- The ... by universal healthcare coverage and good access to ... population and its associated disease burden, well-defined regulatory ... introduction of a new manufacturing policy will drive ... However, a focus on generic substitution and price ...
(Date:9/2/2014)... , Sept. 2, 2014  Cyberonics, Inc. ... from the ANTHEM-HF clinical study.  Results of the ... during a major European cardiology congress and concurrently ... show Autonomic Regulation Therapy (ART) in patients ... impaired heart function is safe, improves the heart,s ...
(Date:9/2/2014)... , Sept. 2, 2014  Based on ... treatment device market, Frost & Sullivan recognizes Novian ... & Sullivan Award for Technology Innovation Leadership. Novian ... fibroadenoma and malignant tumors with its proprietary technology, ... is a reliable, accurate, and easy-to-control ultrasound-guided thermo ...
Breaking Medicine Technology:Australia Medical Devices Market worth $10.4 billion by 2020 Says a New Report Available at MarketOptimizer.org 2Australia Medical Devices Market worth $10.4 billion by 2020 Says a New Report Available at MarketOptimizer.org 3Australia Medical Devices Market worth $10.4 billion by 2020 Says a New Report Available at MarketOptimizer.org 4Australia Medical Devices Market worth $10.4 billion by 2020 Says a New Report Available at MarketOptimizer.org 5ANTHEM-HF Shows Autonomic Regulation Therapy Is Safe And Improves Heart Function In Patients With Chronic Heart Failure 2ANTHEM-HF Shows Autonomic Regulation Therapy Is Safe And Improves Heart Function In Patients With Chronic Heart Failure 3ANTHEM-HF Shows Autonomic Regulation Therapy Is Safe And Improves Heart Function In Patients With Chronic Heart Failure 4ANTHEM-HF Shows Autonomic Regulation Therapy Is Safe And Improves Heart Function In Patients With Chronic Heart Failure 5Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors 2Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors 3Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors 4Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors 5
... , CINCINNATI , June 21 ... to its HARMONIC® line of surgical devices, the HARMONIC ... designed to extend the reach of surgeons for minimally ... (or 9cm) than the standard length HARMONIC ACE® device. ...
... today announced that six-month clinical follow-up data show the safety and ... (Sequent Please®, B.Braun) followed by implantation of the company,s Genous Bio-engineered ... , , ... single center, all-comers POTENT ( P aclitaxel-eluting ball O on and ...
Cached Medicine Technology:Ethicon Endo-Surgery Introduces HARMONIC ACE® 45 cm Curved Shears at ASMBS 2Ethicon Endo-Surgery Introduces HARMONIC ACE® 45 cm Curved Shears at ASMBS 3Data Show OrbusNeich's Genous™ Bio-engineered R stent™ is Safe and Effective in Combination with Drug-Eluting Balloon 2Data Show OrbusNeich's Genous™ Bio-engineered R stent™ is Safe and Effective in Combination with Drug-Eluting Balloon 3
(Date:9/2/2014)... 2014 Recently, Top 10 Best ... and announced that JustHost ( http://www.justhost.com/track/seohosts ) and ... , “The hosting suppliers we recommend are the ... on hosting features, uptime and server speed with ... SEO Hosting says. “We believe that BlueHost and ...
(Date:9/2/2014)... DC (PRWEB) September 02, 2014 TCG, a ... by Inc. 5000 as one of the fastest-growing companies in ... eighth time total. TCG was previously recognized in 2013, 2012, ... , TCG’s revenue has grown 86% from 2010 to 2013, ... the fastest growing businesses in America - up 635 spots ...
(Date:9/2/2014)... Cloud Medical Doctor Software Corporation (Cloud-MDs) ... Practice Business Operations solutions and Billing Services for the ... solutions for all industries announced today that its CEO ... of the CME in Chicago by PRICE Futures Group ... are very proud of the recognition that our CipherLoc ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 The Wm. Jennings ... fair and public town hall meeting for Veterans and their ... at the outreach fair to provide Veterans with valuable healthcare ... “The town hall will provide a forum where we can ... programs.” , The outreach fair will be held 4:45 p.m. ...
(Date:9/2/2014)... News) -- Complications are rare among breast cancer ... study indicates. However, the researchers did find ... slightly higher risk for certain complications than a ... 18,000 breast cancer patients who had a single ... reconstruction and were followed for 30 days after ...
Breaking Medicine News(10 mins):Health News:TCG One of the Fastest-Growing Companies in America – for the Eighth Time! 2Health News:Cloud Medical Doctor Software Corporation's CEO Interviewed by the Price Futures Group 2Health News:Cloud Medical Doctor Software Corporation's CEO Interviewed by the Price Futures Group 3Health News:Complication Rates Low With Mastectomy, Breast Reconstruction: Study 2
... of some on the market , WEDNESDAY, Oct. 14 (HealthDay ... House Office of Management and Budget, is reported to drink ... genetic test to see if his body could metabolize his ... body is perfectly suited to the task, and Orszag can ...
... emerged from 47,000 votes on over 700 essay entries as ... essay contest. The essay contest awards each winner $1,000 ... make life easier for those affected by breast cancer. , ... memory to taking a supportive child to Disney World to ...
... ... hold employment to persevere in this difficult job market. Profiles International suggests that employees ... , ... October 14, 2009 -- Profiles International, a developer of employee assessments and ...
... ... in Class Alzheimer,s Care , ... Neenah, Wisc. (Vocus) October 14, 2009 -- Tracy Hoffman, M.D., one of the nation,s premier ... innovator with 16 facilities in Wisconsin and Illinois. , , , , ,As Corporate Director ...
... ... sleeping problems report better sleep with Gene-Eden, a natural supplement that targets many common chronic ... Rochester, NY (PRWEB) ... natural antiviral Gene-Eden. Analysis of the interviews revealed that the users of the supplement experience ...
... ... Management,(School for Managers) to be held at Sheraton, Wakefield, MA, , ... Boston, MA (PRWEB) October 14, 2009 ... training program, ,Strategic Problem Solving & Advanced Time Management, to be held Wednesday, November ...
Cached Medicine News:Health News:Are Commercial Genetic Tests Worth Taking? 2Health News:Are Commercial Genetic Tests Worth Taking? 3Health News:Fifteen Women Win National O-Cedar(R) Essay Contest 2Health News:As Unemployment Continues to Rise, Profiles International Encourages Employers and Employees to Focus on Value 2Health News:As Unemployment Continues to Rise, Profiles International Encourages Employers and Employees to Focus on Value 3Health News:Renowned Geriatrician Tracy Hoffman Tapped as Corporate Director of Memory Care Excellence By Fast-Growing CRL 2Health News:Renowned Geriatrician Tracy Hoffman Tapped as Corporate Director of Memory Care Excellence By Fast-Growing CRL 3Health News:Users of Gene-Eden, a Natural Antiviral, Report less Sleeping Problems in a Recent Study 2Health News:Users of Gene-Eden, a Natural Antiviral, Report less Sleeping Problems in a Recent Study 3Health News:One Day Management Training Program to be Offered November 18 in Boston Area 2Health News:One Day Management Training Program to be Offered November 18 in Boston Area 3Health News:One Day Management Training Program to be Offered November 18 in Boston Area 4Health News:One Day Management Training Program to be Offered November 18 in Boston Area 5
... system delivers on the promise of ... the latest advancement in fluidics control ... Lomb Surgical offers CONCENTRIX™ Fluidics Control ... provide both flow and vacuum response. ...
... excellent maneuverability. Konan made it ... high quality. Easy switchover from ... changing the adapter. Konan's development ... in a sharp image from ...
To maintain the conjunctival cul-de-sacs after enucleation or evisceration without hindering lid closure....
... These plugs are coated with ... (PVP) that makes the surface ... drainage and to prevent debris ... For partial occlusion. For partial ...
Medicine Products: